TSHR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2778	0.52	9/20
Triclofenol (SCHEMBL1338)	1.00	8/20
Pentachlorophenol (SCHEMBL1492)	1.00	8/20
Mitotane (SCHEMBL4040)	1.00	7/20
Mitotane (SCHEMBL4041)	1.00	7/20
Reserpine (SCHEMBL2589)	1.00	6/20
Benzoyl Peroxide (SCHEMBL63)	0.64	6/20
SCHEMBL3075	0.56	6/20
SCHEMBL3961	0.53	6/20
SCHEMBL3469	0.51	6/20
SCHEMBL1237	0.46	6/20
SCHEMBL644	1.00	5/20
Mevastatin (SCHEMBL1116)	1.00	5/20
SCHEMBL2313	1.00	5/20
Decanal (SCHEMBL2540)	1.00	5/20
Lovastatin (SCHEMBL3136)	1.00	5/20
Lovastatin (SCHEMBL3137)	1.00	5/20
Octanedioate (SCHEMBL3301)	1.00	5/20
SCHEMBL3471	1.00	5/20
Procaine (SCHEMBL3524)	1.00	5/20

Clinical trials — most relevant to TSHR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neurocognitive and Metabolic Effects of Mild Hypothyroidism	PHASE4	COMPLETED
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)	PHASE4	COMPLETED
Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction	PHASE4	COMPLETED
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)	PHASE2/PHASE3	UNKNOWN
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease	PHASE2/PHASE3	COMPLETED
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease	PHASE3	RECRUITING
Trial of Rituximab for Graves' Ophthalmopathy	PHASE2/PHASE3	COMPLETED
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease	PHASE2	RECRUITING
Efficacy and Safety of Tocilizumab for TAO	PHASE2	WITHDRAWN
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities	PHASE2	COMPLETED
Thyroid and Glucose and Energy Metabolism	PHASE2	COMPLETED
A Study of IBI3031 in Participants With Thyroid Eye Disease	PHASE1	NOT_YET_RECRUITING
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism	PHASE1	ACTIVE_NOT_RECRUITING
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer	PHASE1	WITHDRAWN
Natural History of Thyroid Function Disorders	nan	RECRUITING
TSH Receptor Mutations Among a Consanguineous Community	nan	COMPLETED
HIFU vs RAI in the Relapsed Graves' Disease	nan	COMPLETED
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment	nan	COMPLETED
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3	nan	COMPLETED
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy	nan	COMPLETED
Maternal Autoimmune Thyroid Disease and Fetal Thyroxin	nan	COMPLETED
Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine	nan	RECRUITING
Rubus Sanctus (Wild Blackberry) Root Extract as a Dietary Supplement for Graves' Disease	nan	COMPLETED
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism	nan	RECRUITING
Thyroid Function in Liver Cirrhosis: Is it Affected?	nan	COMPLETED
Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism	nan	WITHDRAWN
Observation in the Treatment of Graves' Disease	nan	UNKNOWN
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly	nan	COMPLETED
Short Term Outcome of Metabolic Associated Fatty Liver Disease (MAFLD) in Patients Undergoing Bariatric Surgery	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TSHR binder may also engage these)

Protein	Name	Similarity
Q9BGN4	—	1.000	Q9BGN4 →
P47750	—	1.000	P47750 →
Q27987	—	1.000	Q27987 →
P21463	—	1.000	P21463 →
Q8SPP9	—	1.000	Q8SPP9 →
P14763	—	1.000	P14763 →
P56495	—	1.000	P56495 →
Q6QMG1	—	0.999	Q6QMG1 →
LHCGR	Lutropin-choriogonadotropic hormone receptor	0.997	landscape →
P16582	—	0.994	P16582 →
Q6R6L8	—	0.994	Q6R6L8 →
Q90674	—	0.992	Q90674 →
P30730	—	0.992	P30730 →
O02721	—	0.992	O02721 →
P35378	—	0.990	P35378 →
P20395	—	0.990	P20395 →
P16235	—	0.989	P16235 →
Q28005	—	0.989	Q28005 →
Q95179	—	0.989	Q95179 →
P49059	—	0.988	P49059 →
P47799	—	0.987	P47799 →
Q28585	—	0.985	Q28585 →
Q6YNB6	—	0.984	Q6YNB6 →
FSHR	Follicle-stimulating hormone receptor	0.984	landscape →
P32212	—	0.982	P32212 →
RXFP2	Relaxin receptor 2	0.982	landscape →
P35376	—	0.981	P35376 →
Q8R428	—	0.981	Q8R428 →
Q5XM32	—	0.980	Q5XM32 →
Q5GJ04	—	0.980	Q5GJ04 →